DaVita EBIT 2010-2024 | DVA

DaVita annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
  • DaVita EBIT for the quarter ending September 30, 2024 was $0.535B, a 7.85% increase year-over-year.
  • DaVita EBIT for the twelve months ending September 30, 2024 was $1.915B, a 30.35% increase year-over-year.
  • DaVita 2023 annual EBIT was $1.603B, a 19.69% increase from 2022.
  • DaVita 2022 annual EBIT was $1.339B, a 25.5% decline from 2021.
  • DaVita 2021 annual EBIT was $1.797B, a 6.06% increase from 2020.
DaVita Annual EBIT
(Millions of US $)
2023 $1,603
2022 $1,339
2021 $1,797
2020 $1,695
2019 $1,643
2018 $1,526
2017 $1,813
2016 $2,030
2015 $1,137
2014 $1,815
2013 $1,550
2012 $1,297
2011 $1,155
2010 $994
2009 $940
DaVita Quarterly EBIT
(Millions of US $)
2024-09-30 $535
2024-06-30 $506
2024-03-31 $484
2023-12-31 $390
2023-09-30 $496
2023-06-30 $405
2023-03-31 $312
2022-12-31 $256
2022-09-30 $312
2022-06-30 $433
2022-03-31 $338
2021-12-31 $389
2021-09-30 $475
2021-06-30 $490
2021-03-31 $443
2020-12-31 $382
2020-09-30 $438
2020-06-30 $410
2020-03-31 $465
2019-12-31 $463
2019-09-30 $378
2019-06-30 $462
2019-03-31 $341
2018-12-31 $388
2018-09-30 $289
2018-06-30 $438
2018-03-31 $411
2017-12-31 $150
2017-09-30 $395
2017-06-30 $391
2017-03-31 $876
2016-12-31 $517
2016-09-30 $819
2016-06-30 $329
2016-03-31 $365
2015-12-31 $211
2015-09-30 $509
2015-06-30 $481
2015-03-31 $-64
2014-12-31 $452
2014-09-30 $438
2014-06-30 $484
2014-03-31 $441
2013-12-31 $484
2013-09-30 $377
2013-06-30 $522
2013-03-31 $167
2012-12-31 $388
2012-09-30 $341
2012-06-30 $247
2012-03-31 $321
2011-12-31 $354
2011-09-30 $319
2011-06-30 $247
2011-03-31 $235
2010-12-31 $252
2010-09-30 $257
2010-06-30 $242
2010-03-31 $243
2009-12-31 $238
2009-09-30 $245
2009-06-30 $236
2009-03-31 $221
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $12.667B $12.140B
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $20.039B 12.12
Quest Diagnostics (DGX) United States $17.877B 18.12
Encompass Health (EHC) United States $10.405B 24.53
Chemed (CHE) United States $8.459B 26.00
Elanco Animal Health (ELAN) United States $7.054B 16.79
RadNet (RDNT) United States $6.388B 141.61
Option Care Health (OPCH) United States $3.890B 18.43
Amedisys (AMED) United States $3.035B 21.60
LifeStance Health (LFST) United States $2.828B 0.00
Addus HomeCare (ADUS) United States $2.320B 27.22
Astrana Health (ASTH) United States $2.297B 36.01
U.S Physical Therapy (USPH) United States $1.428B 37.54
Pennant (PNTG) United States $1.162B 46.99
Aveanna Healthcare Holdings (AVAH) United States $1.149B 0.00
Atai Life Sciences (ATAI) Germany $0.265B 0.00
Daxor (DXR) United States $0.042B 0.00
Psychemedics (PMD) United States $0.014B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.014B 0.00
ATI Physical Therapy (ATIP) United States $0.011B 0.00
Ontrak (OTRK) United States $0.008B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00